Event-Driven Stocks

Atara Biotherapeutics, Inc.

ATRANasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$120.8M$128.9M$8.6M$63.6M——
Operating income$35.9M−$83.4M−$276.0M−$280.5M−$340.5M−$309.1M
Net income$32.7M−$85.4M−$276.1M−$228.3M−$340.1M−$306.6M
Total assets$20.2M$109.1M$165.5M$376.4M$468.1M$588.1M
Total liabilities$58.7M$206.4M$264.7M$249.8M$188.5M$125.8M
Equity−$38.5M−$97.3M$99.2M$126.6M$279.6M$462.3M
EPS (diluted)$2.57$-11.41$-65.19$-2.24$-3.63$-4.15
Shares out.5.9M119.4M95.9M93.1M83.6M58.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
29.7%
Net margin
27.1%
Return on equity
−84.9%
Return on assets
161.5%
Return on capital (ROCE)
675.0%
Liabilities / assets
290.3%
Debt / equity
—
Book value / share
$-6.57
Revenue growth (YoY)
−6.3%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-315.39distress
Accruals / assets
413.3%high accruals
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
29
/ 100
Profitability 80Growth 0Catalyst 67Earnings quality 0Financial strength 0

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 2 severe● 4 warning● 1 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Operating margin is positive

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026546,4701.0+78.5%
Apr 30, 2026306,0936.1-3.7%
Apr 15, 2026317,9534.1-2.8%
Mar 31, 2026327,0663.0+4.4%
Mar 13, 2026313,2901.0-5.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.